Physician profile
Joanna Bartholomew
NPI 1932554961
$2,190.69
in general payments reported to CMS, 2019-2025
23 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.88 · 2020: $56.14 · 2021: $20.03 · 2022: $14.04 · 2024: $989 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $364.18 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $282.03 | 2020-2025 | |
| Novo Nordisk INC | $213.51 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $143.56 | 2024-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $76.77 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $73.21 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Sumitomo Pharma America, INC. | $67.36 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $63.83 | 2025 | Rexulti |
| Antares Pharma, INC. | $54.57 | 2024-2025 | Xyosted |
| Lundbeck LLC | $52.00 | 2024 | Rexulti |
| Amgen INC. | $49.01 | 2024-2025 | Repatha, Otezla, Otezla |
| Almatica Pharma LLC | $47.35 | 2024 | Loreev Xr |
| Axsome Therapeutics, INC. | $36.02 | 2025 | Symbravo |
| Sanofi-Aventis U.S. LLC | $30.36 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22.97 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $22.79 | 2025 | Zenpep |
| Abbott Laboratories | $19.40 | 2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $18.66 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $15.62 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Currax Pharmaceuticals LLC | $14.15 | 2025 | Contrave, Onzetra Xsail |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.02 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Bartholomew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.